Skip to main content
Top
Published in: Digestive Diseases and Sciences 9/2014

01-09-2014 | Original Article

Genetic Mechanisms in Interval Colon Cancers

Authors: James M. Richter, Maria Simona Pino, Thomas R. Austin, Emily Campbell, Jackie Szymonifka, Andrea L. Russo, Theodore S. Hong, Darrell Borger, A. John Iafrate, Daniel C. Chung

Published in: Digestive Diseases and Sciences | Issue 9/2014

Login to get access

Abstract

Background and Aim

The factors underlying the development of interval colon cancers are not well defined and are likely heterogeneous. We sought to determine whether there are distinct molecular properties associated with interval colon cancers.

Methods

Colon cancers diagnosed within 5 years of a complete and well-prepped colonoscopic examination were identified over a 7-year period at a single institution. The clinical and pathological features of the tumors were defined. Analysis of DNA mismatch repair (MMR) and genotyping of a panel of oncogenes associated with colon cancer were performed.

Results

Forty-two interval colon cancers were diagnosed at an average age of 70 years. 69 % of tumors were located in the right colon. 41 % of tumors exhibited DNA microsatellite instability (MSI). Loss of staining of DNA MMR proteins by immunohistochemistry (IHC) was confirmed in 82 % of the MSI-positive tumors. Among tumors with abnormal MSI and IHC, 54 % exhibited somatic methylation of the MLH1 promoter, but the remaining 43 % exhibited molecular features indicative of underlying Lynch syndrome (LS). The frequency of somatic mutations in the KRAS, BRAF, NRAS, and PIK3CA oncogenes was similar between interval cancer cases and controls.

Conclusions

Interval colon cancers are not distinguished by the activation of the KRAS, NRAS, BRAF, or PIK3CA oncogenic pathways. However, MSI pathway defects are present in a significant proportion of interval colon cancers. Underlying LS may explain nearly half of these MSI-positive cases, and the remaining cases appear to represent sporadic serrated pathway tumors.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.PubMedCentralPubMedCrossRef Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.PubMedCentralPubMedCrossRef
3.
go back to reference Pignone M, Rich M, Teutsch S, Berg A, Lohr K. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:132–141.PubMedCrossRef Pignone M, Rich M, Teutsch S, Berg A, Lohr K. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:132–141.PubMedCrossRef
4.
go back to reference Smith R, Cokkinides V, Brawley O. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41.PubMedCrossRef Smith R, Cokkinides V, Brawley O. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41.PubMedCrossRef
5.
go back to reference Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560.PubMedCrossRef Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560.PubMedCrossRef
6.
go back to reference Zauber A, Winawer S, O’Brien M. Significant long term reduction in colorectal cancer mortality with colonoscopic polypectomy: findings of the National Polyp Study. Gastroenterology. 2007;132:A50.CrossRef Zauber A, Winawer S, O’Brien M. Significant long term reduction in colorectal cancer mortality with colonoscopic polypectomy: findings of the National Polyp Study. Gastroenterology. 2007;132:A50.CrossRef
7.
go back to reference Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–696.PubMedCentralPubMedCrossRef Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–696.PubMedCentralPubMedCrossRef
8.
go back to reference Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.PubMedCrossRef Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.PubMedCrossRef
9.
go back to reference Rex DK. Maximizing detection of adenomas and cancers during colonoscopy. Am J Gastroenterol. 2006;101:2866–2877.PubMedCrossRef Rex DK. Maximizing detection of adenomas and cancers during colonoscopy. Am J Gastroenterol. 2006;101:2866–2877.PubMedCrossRef
10.
go back to reference Jass JR, Stewart SM, Stewart J, Lane MR. Hereditary non-polyposis colorectal cancer—morphologies, genes and mutations. Mutat Res. 1994;310:125–133.PubMedCrossRef Jass JR, Stewart SM, Stewart J, Lane MR. Hereditary non-polyposis colorectal cancer—morphologies, genes and mutations. Mutat Res. 1994;310:125–133.PubMedCrossRef
11.
go back to reference Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut. 2002;50:382–386.PubMedCentralPubMedCrossRef Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut. 2002;50:382–386.PubMedCentralPubMedCrossRef
12.
go back to reference Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut. 2002;50:228–234.PubMedCentralPubMedCrossRef Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut. 2002;50:228–234.PubMedCentralPubMedCrossRef
13.
go back to reference Farris AB III, Demicco EG, Le LP, et al. Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. Am J Surg Pathol. 2011;35:647–655.PubMedCrossRef Farris AB III, Demicco EG, Le LP, et al. Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. Am J Surg Pathol. 2011;35:647–655.PubMedCrossRef
14.
go back to reference Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146–158.PubMedCentralPubMedCrossRef Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146–158.PubMedCentralPubMedCrossRef
15.
go back to reference Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–195.PubMedCrossRef Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–195.PubMedCrossRef
16.
go back to reference Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98–99.PubMedCrossRef Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98–99.PubMedCrossRef
17.
go back to reference Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50:307–312.PubMedCrossRef Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50:307–312.PubMedCrossRef
18.
go back to reference Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104:18654–18659.PubMedCentralPubMedCrossRef Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104:18654–18659.PubMedCentralPubMedCrossRef
19.
go back to reference Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–1857.PubMedCrossRef Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–1857.PubMedCrossRef
20.
go back to reference Patel SG, Ahnen DJ. Prevention of interval colorectal cancers: what every clinician needs to know. Clin Gastroenterol Hepatol. 2014;12:7–15.PubMedCrossRef Patel SG, Ahnen DJ. Prevention of interval colorectal cancers: what every clinician needs to know. Clin Gastroenterol Hepatol. 2014;12:7–15.PubMedCrossRef
21.
go back to reference Gonzalez EC, Roetzheim RG, Ferrante JM, Campbell R. Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum. 2001;44:251–258.PubMedCrossRef Gonzalez EC, Roetzheim RG, Ferrante JM, Campbell R. Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum. 2001;44:251–258.PubMedCrossRef
22.
go back to reference Fleshner P, Slater G, Aufses AH Jr. Age and sex distribution of patients with colorectal cancer. Dis Colon Rectum. 1989;32:107–111.PubMedCrossRef Fleshner P, Slater G, Aufses AH Jr. Age and sex distribution of patients with colorectal cancer. Dis Colon Rectum. 1989;32:107–111.PubMedCrossRef
23.
go back to reference Pabby A, Schoen RE, Weissfeld JL, et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc. 2005;61:385–391.PubMedCrossRef Pabby A, Schoen RE, Weissfeld JL, et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc. 2005;61:385–391.PubMedCrossRef
24.
go back to reference Huang Y, Gong W, Su B, Zhi F, Liu S, Jiang B. Risk and cause of interval colorectal cancer after colonoscopic polypectomy. Digestion. 2012;86:148–154.PubMedCrossRef Huang Y, Gong W, Su B, Zhi F, Liu S, Jiang B. Risk and cause of interval colorectal cancer after colonoscopic polypectomy. Digestion. 2012;86:148–154.PubMedCrossRef
25.
go back to reference Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol. 2006;4:1259–1264.PubMedCrossRef Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol. 2006;4:1259–1264.PubMedCrossRef
27.
go back to reference Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol. 2010;105:1189–1195.PubMedCrossRef Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol. 2010;105:1189–1195.PubMedCrossRef
28.
go back to reference Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.PubMedCrossRef Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.PubMedCrossRef
29.
go back to reference Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257.PubMed Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257.PubMed
30.
go back to reference Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–2100.PubMedCrossRef Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–2100.PubMedCrossRef
31.
go back to reference Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M. Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci. 2010;55:2352–2356.PubMedCrossRef Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M. Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci. 2010;55:2352–2356.PubMedCrossRef
32.
go back to reference Shaukat A, Arain M, Anway R, Manaktala S, Pohlman L, Thyagarajan B. Is KRAS mutation associated with interval colorectal cancers? Dig Dis Sci. 2012;57:913–917.PubMedCrossRef Shaukat A, Arain M, Anway R, Manaktala S, Pohlman L, Thyagarajan B. Is KRAS mutation associated with interval colorectal cancers? Dig Dis Sci. 2012;57:913–917.PubMedCrossRef
33.
go back to reference Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2013;13:01195–01196. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2013;13:01195–01196.
Metadata
Title
Genetic Mechanisms in Interval Colon Cancers
Authors
James M. Richter
Maria Simona Pino
Thomas R. Austin
Emily Campbell
Jackie Szymonifka
Andrea L. Russo
Theodore S. Hong
Darrell Borger
A. John Iafrate
Daniel C. Chung
Publication date
01-09-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3134-2

Other articles of this Issue 9/2014

Digestive Diseases and Sciences 9/2014 Go to the issue

GRG Profiles and Perspectives

GRG Profiles: Professor Ignazio Marino

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.